First-of-Its Kind Pharmacokinetics Study On Cannabinoids For Dogs
Cornell University’s College of Veterinary Medicine has just announced the findings of the first-ever pharmacokinetic clinical trial examining the effects of cannabinoids in dogs.
The participating dogs in the study were experiencing joint discomfort. To conduct the 8-month double blind, placebo controlled study, Cornell collaborated with ElleVet Sciences. ElleVet Sciences was founded in Portland in 2017, and is in the business of creating soft-chew supplements for dogs made from proprietary hemp oil blends. The primary goal of the Cornell-ElleVet study was to understand how dogs metabolized ElleVet Mobility Soft Chews, which are hemp-based supplements also containing glucosamine and chondroitin, two natural compounds that may improve mobility in dogs.
The study findings represent a meaningful step forward in understanding how cannabinoids are processed in dogs. The trial also places ElleVet Sciences at the forefront of the growing body of research on how CBD + CBDA and other natural compounds can help animals live happier, healthier lives.
Read More About the CBD + CBDA Studies Conducted by ElleVet Sciences>
Copy and paste link to view full study: https://www.mdpi.com/2076-2615/9/10/832
About ElleVet Sciences: ElleVet Sciences is a leading science-driven animal health company headquartered in South Portland, Maine. As the first and only organization to conduct successful clinical trials on the safety and efficacy of CBD + CBDA for pets, ElleVet continues to lead the field through research and innovation in collaboration with top veterinary professionals and institutions. The company has pioneered and patented safe, effective products for dogs, cats, and horses, offering support for mobility, stress, canine skin health, and canine brain function. Carried by thousands of veterinary clinics across the US, ElleVet is committed to improving the lives of companion animals, with both heart and science at the core of its mission.
###